CAPItello-281: Capivasertib plus abiraterone and ADT improves rPFS in PTEN-deficient mHSPC

Genitourinary Cancer

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Ann Oncol

Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ, CAPItello-281 Study Group

doi: 10.1016/j.annonc.2025.10.004

SABCS 2024

Breast Cancer

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

Genitourinary Cancer

Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial

J Clin Oncol

Saad F, Shore ND, Vjaters E, Olmos D, Littleton N, Liu A, Testa I, Mo M, Srinivasan S, Parambath Haresh K

doi: 10.1200/JCO.2025.43.5_suppl.15

Genitourinary Cancer

Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS

J Clin Oncol

Carles J, Tombal BF, Hussain MHA , Saad F, Fizazi K, Montesa Pino A, Méndez-Vidal MJ, Rodriguez-Vida A, Castellano D, Borrega P, Adorjan P, Moretones C, Dissanayake M, Smith MR

doi: 10.1200/JCO.2025.43.5_suppl.143

SPECIAL REPORT

Genitourinary Cancer

EMBARK: Impact of Enzalutamide Plus ADT on Clinical Practice in Biochemically Recurrent Prostate Cancer

ESMO 2025

Genitourinary Cancer

ARASAFE: Lower docetaxel dose improves safety in patients with mHSPC

Genitourinary Cancer

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Lancet

Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N

doi: 10.1016/S0140-6736(25)00683-X

SABCS 2024

Breast Cancer

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

ESMO 2025

Genitourinary Cancer

Related content

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial

Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS

EMBARK: Impact of Enzalutamide Plus ADT on Clinical Practice in Biochemically Recurrent Prostate Cancer

ARASAFE: Lower docetaxel dose improves safety in patients with mHSPC

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

EMBARK: Enzalutamide plus leuprolide significantly improves OS in high-risk biochemically recurrent prostate cancer